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HCV treatment is associated with significant health care resource utilization. A high 
proportion of patients experienced AE for which management was associated with 
substantial additional costs, especially the anemia treatment. Thus, the cost of AE 
should be considered in future treatment options.
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Objectives: Estimate the direct cost of hepatitis C in Mexico, from the perspective 
of the health care system for the government employees, and simulate the economic 
impact of new antivirals. MethOds: We reviewed one hundred clinical records of 
patients diagnosed with chronic hepatitis C, to know the pattern of resources use at 
two hospitals of the health care system for the government employees, taking into 
account the disease stages based on the Child-Pugh. The inclusion criterion was 
patients with chronic HVC unresponsive to treatment or without the double viral 
therapy. Unit prices and costs of medical inputs were obtained from official sources. 
Demographic and clinical variables were also recorded in order to do compari-
sons. Statistical analysis of data was made with the SPSS. Simulation of economic 
impact of treatment with antivirals was done based on natural history of disease 
over a ten years horizon. Results: Annual mean costs of disease progression and 
complications were higher for Child-Pugh C (US$8,739) than B (US$6,319) and A 
(US$2,430). The estimated cost of one patient in Child-Pugh A stage not responding 
to peginterferon and ribavirin resulted in US$62,506 taking into account that this 
patient progress until Child-Pugh C. If the not responding patient could be treated 
with peginterferon, ribavirin and boceprevir the cost would be US$43,633, while a 
naive patient would cost US$34,302. cOnclusiOns: Hepatitis C imposes a high 
economic burden to the health care system for the government employees. The 
access of this population of patients to new antivirals would result in savings for 
the institution as well as increasing health benefits for patients.
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Objectives: To assess the potential trade-offs between aggressive screening (“test-
ing”) of the human immunodeficiency virus (HIV), early initiation of treatment 
(“test-and-treat”) with antiretroviral therapy (ART), and pre-exposure prophy-
laxis (PrEP) among men who have sex with men (MSM) in Los Angeles County 
(LAC). MethOds: A compartmental mathematical model is developed to simulate 
HIV incidence among 15-65 year old MSMs of LAC over a twenty-year period, and 
estimate the cost and effectiveness of various HIV interventions using a societal 
perspective and a lifetime horizon. Annual LAC MSM population data (2000-2010) 
are estimated from the LAC HIV Surveillance Reports and the RAND California 
Population and Demographics database. The model input parameter values are 
derived from the published clinical literature and the Federal Supply and IMS Fee 
Schedules. For each intervention, we estimate the number of new HIV infections 
averted, the discounted costs and quality-adjusted life years (QALYs), and the incre-
mental cost per infection averted and cost-effectiveness ratios. Bootstrapping and 
probabilistic sensitivity analyses are conducted to assess the robustness of the 
estimates. Results: Our preliminary results show that relative to the status quo 
policy, and at the current US willingness to pay threshold of $100,000/QALY saved, 
both the PrEP, “testing” and “test-and-treat” strategies are cost-effective ($86,194; 
$44,746 and $94,520 per QALY saved, respectively). These results are imputable to 
the preventive and survival benefits of PrEP, knowledge of infection status, and early 
treatment. The relative effectiveness of PrEP is sensitive to PrEP and ART adherence 
and coverage rates. All cost-effectiveness profiles improve with ART price reductions 
following patent expiration. cOnclusiOns: PrEP, “testing” and “test-and-treat” 
offer cost-effective alternatives to the status-quo policy. The success of the PrEP 
and “test-and-treat” strategies remains particularly contingent on the uptake rate 
and adherence to treatment. The lack of evidence on adherence behaviors towards 
PrEP thus warrants further studies that mimic real-world adherence patterns.
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Objectives: Determine the cost-effectiveness of small intestinal submucosa extra-
cellular matrix (SISEM) relative to standard of care (SC) on wound closure for the 
treatment of mixed arterial/venous (A/V) or venous (VLUs) leg ulcers. MethOds: 
A 2-stage Markov model was used to predict the expected costs and outcomes of 
wound closure for SISEM and SC. Outcome data used in the analysis were taken 
from an 8-week randomized clinical trial that directly compared SISEM and SC. 
Patients were followed for 6 months to assess wound closure. Forty-eight patients 
completed the study; 25 for SISEM and 23 for SC. SC was defined as a standard moist 
wound dressing. Transition probabilities for the Markov states were estimated from 
the clinical trial. The economic outcome of interest was direct cost per ulcer-free 
week. Resource utilization was based on the treatment regimen used in the clini-
cal trial. Costs were derived from standard cost references. The payer’s perspective 
was taken. Results: SISEM-treated wounds healed, on average, after 5.4 weeks of 
treatment, compared to 8.3 weeks for SC wounds (p= 0.02). Furthermore, complete 
wound closure was significantly higher for patients treated with SISEM (p< 0.05), 
with 20 wounds closed in the SISEM group (80%) and 15 wounds closed in the SC 
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Objectives: Pertussis incidence has resurged in the US after a nadir in the 1970s 
and is now one of the most prevalent vaccine-preventable infections. Infants are 
at greatest risk for severe pertussis-related morbidity and mortality (~50% of infant 
cases require hospitalization) and account for the majority of cases. We sought to 
quantify the cost and mortality burden of infant pertussis cases severe enough 
to prompt hospitalization. MethOds: Data on pertussis-related hospitalizations 
(ICD-9-CM discharge codes 033.0, 033.8, 033.9, 484.3) from the 2000-2010 Nationwide 
Inpatient Sample (NIS) were retrospectively analyzed. Charges were converted to 
costs using a 0.5 cost-to-charge ratio. Weighted, nationally representative estimates 
of costs per admission (in 2013 US dollars), length of stay (LOS), and case fatality 
rates (CFRs) were descriptively assessed for each year. Results: Total numbers 
of infant pertussis hospitalizations in the US followed a cyclic pattern, starting at 
2,282 in 2000 and peaking at 5,343 in 2005, then declining to 1,614 in 2007 before 
another peak of 3,220 in 2010. Mean [SD] LOS for these hospitalizations fluctuated 
minimally year-to-year, but an overall (albeit modest) increase was observed: from 
3.3 [7.3] days in 2000 to 3.9 [9.5] days in 2010. Mean [SD] cost per admission increased 
at a greater rate than LOS, from $12,377 [$23,985] in 2000 to $16,339 [$37,224] in 2010. 
Both LOS and costs were more than double those observed for non-pertussis hospi-
talizations. CFRs were relatively stable during the period, fluctuating between ~1.5% 
and 3%, although a peak of 4.4% occurred in 2005 coinciding with the incidence 
peak. cOnclusiOns: Infant pertussis hospitalizations typically exceed 3 days and 
are associated with high costs compared with hospitalizations for other causes. 
Observed CFRs were consistent with the ~2% fatality rate previously derived from 
CDC surveillance. These data may help inform economic and cost-effectiveness 
evaluations of future pertussis vaccination programs.
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Objectives: To estimate the direct medical costs associated with the use of eryth-
ropoietin (EPO) in the treatment of anemia in patients with advanced fibrosis and 
cirrhosis (METAVIR F3-F4) receiving telaprevir in association with peg-interferon and 
ribavirin (TVR+PR) in the early access program in Brazil. MethOds: Anemia events 
and EPO use during TVR therapy were gathered from published results of 97 patients 
in the early access program (EAP) of TVR in Brazil. Anemia treatment was assumed 
to be one vial of erythropoietin (EPO) 40.000U per week. Medication unit costs were 
gathered from a public (SUS) and private payer perspective in Brazil. Sensitivity 
analysis was carried out for anemia treatment duration and patients with EPO 
use. A sub-analysis was performed to estimate the cost of anemia treatment with 
boceprevir (BOC+PR) based on data from the phase 3 clinical trials. Results: The 
cost of EPO during TVR+PR treatment in the EAP /anemic patient was R$ 10.190,04 
from a private payer perspective compared to R$ 3.545,06 from a SUS perspective. 
The average cost of EPO was R$ 4.727,34 /patient from a private payer perspec-
tive and R$ 1.644,87 /patient from the SUS perspective. Considering the sensitivity 
analysis, the total cost of EPO treatment ranged between R$ 382.126,50-R$ 601.212,36 
from a private payer perspective compared to R$ 132.960,00-R$ 209.190,40 from a 
SUS perspective for all patients. Considering EPO use for BOC+PRr, the average ane-
mia treatment cost was R$ 7.851,34 /patient from a private payer perspective and 
R$ 2.731,86 /patient from a SUS perspective. cOnclusiOns: In a real life setting, 
TVR+PR was associated with EPO use although few patients discontinued treatment. 
Compared to EPO use in clinical trials, TVR+PR was associated with less EPO costs 
than BOC+PR in a real life setting such as the Brazilian EAP.
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Objectives: The objective was to estimate, in a real-life setting, the health care 
resource utilization, more specifically resource utilization for management of the 
most common adverse events (AE) associated with current treatment of hepatitis 
C virus (HCV) infection. MethOds: A retrospective study of the Quebec provin-
cial drug reimbursement program (RAMQ) was conducted using a random sample 
of patients who filed at least one script at the pharmacy for an HCV medication 
(pegylated interferon and ribavirin (peg-Riba) +/- boceprevir or telaprevir) from 
2007 to 2013. Data on medical (excluding nurse visits) and pharmaceutical services 
were extracted from the RAMQ database. We report health care resources used 
during HCV treatment including outpatient physician’s visits and procedures, emer-
gency visits, hospitalization days and costs associated with adverse events, which 
included medical services and medications. Results: A total of 962 patients who 
used at least one HCV medication were included in the study (mean age: 47.9 years 
(SD= 10.7), 61.5% males). The proportion of patients who used Peg-Riba only, Peg-
Riba + boceprevir and Peg-Riba + telaprevir was 90.5%, 8.2% and 3.4% and treatment 
duration was 31.5 weeks, 30.4 weeks and 21.6 weeks respectively. During HCV treat-
ment, the average number of health care resources used per patient was 13.2 physi-
cian’s visits and procedures, 0.8 hospitalization day and 0.8 emergency visit. While 
receiving HCV treatment, 20.8% of patients required erythropoietin, 33.3% received 
rash treatments and 48.8% were treated for depression. Estimated costs associated 
with management of these three AE were CDN$11,199, CDN$85 and CDN$282 per 
patient respectively, for a total of CDN$2,399,258 for this cohort. cOnclusiOns: 
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from remission, progression to long-term adverse outcomes (cirrhosis, decompen-
sated cirrhosis, hepatocellular carcinoma, end-stage liver disease) and commonly 
observed side effects (anemia, neutropenia and rash) along with a gradient of their 
severity. Model inputs were determined from a review of the published literature 
and phase II or III clinical trials. Clinical trials estimates were converted to risk ratios 
to facilitate comparison. Costs were inflated to 2013 US dollars. Costs and quality 
adjusted life years were discounted at standard rate of 5%. Sensitivity analyses 
were performed to assess model sensitivity and address uncertainty. Results: 
Relative to treatment with PR only, response-guided triple therapy with BOC+PR 
was the most cost effective therapy (ICER $28,723/QALY) followed by response-
guided triple therapy with TVR+PR (ICER $64,569/QALY). PR treatments with SIM or 
SOF were dominated by BOC+PR. The model was sensitive to variations in costs of 
initial drug therapy and likelihood of attaining SVR. cOnclusiOns: Addition of 
protease inhibitors to PR therapy improves health outcomes. Response-guided regi-
men BOC+PR was found to be cost-effective for treating newly diagnosed genotype 
1 HCV patients. Shortening of PR therapy guided by a rapid virologic response may 
help reduce overall costs. Robust sensitivity analyses can help in overcoming the 
challenge of sparse data availability.
PIN48
cost-effectIveNess of ertaPeNem versus PIPeracIllIN/tazobactamIN 
IN treatING commuNIty acQuIreD INtra-abDomINal INfectIoNs IN 
colombIa
Xie Y.1, Lemos E.2, Restrepo M.2, Ruiz J.2, Lozano F.2
1Merck & Co., Whitehouse Station, NJ, USA, 2MSD Colombia, Bogota, Colombia
Objectives: To compare Ertapenem with piperacillin/tazobactam (pip/tazo) for the 
treatment of moderate to severe community acquired intra-abdominal infections 
(c-IAI) in Colombia health care setting, with respect to cost and outcomes taking 
into account development of anti-microbial resistance (AMR). MethOds: A previ-
ously published decision tree model was adapted to estimate cost-effectiveness 
of Ertapenem vs. pip/tazo. Clinical efficacy, adverse events and medical resource 
use were derived from literature. AMR to Ertapenem and pip/tazo was calculated 
as weighted average based on the % distribution of different pathogens in c-IAI in 
Colombia and the sensitivity of Erta vs. pip/tazo for each pathogen from Colombia 
SMART data. The resistance-adjusted effectiveness is then computed based on effi-
cacy from clinical trial and local AMR data, Model outcomes included resistance, 
clinical success, deaths, life years, direct costs, and costs per successfully treated 
patient. Results: The overall resistance of Ertapenem vs. pip/tazo for c-IAI is 21.4% 
vs. 43.4%. The resistance-adjusted effectiveness are 70.3% vs. 46% for Ertapenem vs. 
pip/tazo. Daily drug costs are 133,550 (Ertapenem) vs. 34,989 (pip/tazo) Colombian 
Pesos. Total costs (including drug costs, hospitalization, cost of 2nd-line treatment 
& cost of AEs) are 7,162,081 (Ertapenem) vs. 7,230,902 (pip/tazo) Pesos. During the 
first hospitalization period, Ertapenem is associated with a 24.3% higher treatment 
success rate, and a 68,821 Pesos in cost saving when compared with Pip/tazo. The 
Incremental cost per successfully treated patient (ICER) is -283,405 Colombian Pesos 
($145.39 USD) for Ertapenem vs. Pip/tazo. cOnclusiOns: Accounting for local anti-
microbial resistance, Ertapenem is more effective and cost-saving vs. pip/tazo for 
the treatment of moderate to severe community acquired intra-abdominal infec-
tions in Colombia.
PIN49
cost-effectIveNess aNalysIs of JoINt vaccINatIoN WItH 13-valeNt 
PNeumococcal coNJuGate vaccINe (Pcv13) aND INflueNza vaccINe IN 
taIWaN DurING seasoNal INflueNza
Wu D.B.C., Chong H.Y., Lee K.K.C.
Monash University Malaysia, Kuala Lumpur, Malaysia
Objectives: Pneumococcal diseases and influenza have caused substantial clini-
cal and economic burden in Taiwan especially in high-risk groups such as infants 
and elderly. It has been shown that influenza can increase the risk of pneumococ-
cal diseases compared to those uninfected during a seasonal influenza. The cost-
effectiveness of PCV13 has been previously established. Influenza vaccine (INFv) is 
generally considered as an effective prevention of influenza and is therefore useful 
in alleviating the burden of influenza in reducing morbidities and mortalities. This 
study aims to evaluate the potential cost-effectiveness of joint 13-valent pneumo-
coccal conjugate vaccine (PCV13) and INFv vs influenza vaccine alone for infants and 
elderly. MethOds: An age-stratified decision tree model was developed to simulate 
clinical and economic impacts of joint vaccination with PCV13 and INFv in newborns 
and elderly compared to influenza vaccine alone during a seasonal influenza over a 
1-year time horizon. Direct medical costs, epidemiological, demographic parameters 
are Taiwan-specific. Effectiveness of vaccines is based on previous trials adjusted for 
local age-specific stereotype distributions. Herd effect estimates were extrapolated 
from the US post-PCV surveillance data. The study was performed from a payer 
perspective. Current market prices of vaccines were used. One-way and multivari-
ate probabilistic sensitivity analyses were performed to identify influential factors 
to outcomes. Results: Compared to influenza vaccination alone, over 1-year time 
horizon, joint vaccination of PCV13 and INFv is predicted to prevent 386 cases of 
invasive pulmonary diseases, 4,232 cases of all-cause pneumonia, 32,652 cases of 
acute otitis media and 202 deaths (equivalent to 3,131 life years). The universal 
vaccination is expected to save NT$352,593,433 (US$11,753,114) in direct medical 
cost equivalent to NT$947,629 (US$31,587) per life year gained. The results are sen-
sitive to vaccine prices and incidence of influenza. cOnclusiOns: Using WHO-
recommended cost-effectiveness threshold, universal vaccination program with 
PCV13 and INFv appears to be a cost-effective policy in Taiwan.
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group (65%). After 6 months, patients treated with SISEM had substantially higher 
ulcer-free weeks compared to SC (20.0 versus 16.8, respectively). Expected direct 
costs per patient were $2,360 for SISEM and $1,326 for SC. The incremental cost-
effectiveness ratio (ICER) for SISEM was $349 (approximately $50/day), indicating 
that for each $349 paid for SISEM therapy patients gained one additional ulcer-free 
week. cOnclusiOns: SISEM yielded better outcomes at a slightly higher cost in 
patients with mixed A/V and VLUs. SISEM is an effective treatment for wound heal-
ing and should be considered for use in the management of mixed A/V and VLUs.
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Objectives: To assess the cost-effectiveness of the introduction of the quadriva-
lent HPV vaccine in Argentina. MethOds: Using a transmission dynamic model 
developed and published by Elbasha in 2008 we evaluated the routine vaccination 
of 11-year-old girls over a time horizon of 100 years from the perspective of the 
health care system Results: The model showed that the introduction of the vac-
cine will gradually reduce the incidence of cervical cancer, CIN 1/2/3, and genital 
warts related to HPV 6/11/16/18. When compared with non-vaccination, a women 
who completed the three dose scheme will experience a reduction of cervical cancer 
incidence and death, CIN2/3, CIN1 and genital warts of 58,6%, 59,2%, 56,7%, 56,3% 
and 67,3% respectively. Considering a 5% discount rate and a 43,8% of complete 
scheme coverage without heard immunity, the incremental cost-effectiveness ratio 
(ICER) was 795 USD per quality-adjusted life-year (QALY) gained. The additional 
protection against HPV types 6/11 has a great influence in the cost-effectiveness, 
the ICER was almost doubled when not contemplated the protection against HPV 
6/11. The most influential parameters on the scenario analysis were the discount 
rate, the cost of the vaccine and the cost of treatment. However, the vaccine was 
very cost-effective (less than one gross domestic product= 7844 USD) in all the tested 
scenarios. cOnclusiOns: The implementation of routine HPV vaccination with 
the quadrivalent vaccine in 11-year-old girls in Argentina could provide significant 
benefits to public health by reducing cervical cancer incidence and death rates 
and the incidence of CIN 1/2/3 and genital warts, making it a highly cost-effective 
intervention
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Objectives: The validation of complex economic models against observational 
cohorts tests the accuracy of structural assumptions in models and the relation-
ship between variables and the validity of model outcomes. However, these exer-
cises are seldom conducted and published. The study objectives were to assess 
how well a newly developed economic model for HIV (ARAMIS-DTG) predicts CD4+ 
cell-count changes and AIDS-related outcomes and to explore drivers of eventual 
discrepancies between simulated and observed outcomes. MethOds: Clinical out-
comes from ARAMIS-DTG were compared to an observational cohort of patients 
initiating antiretroviral treatment in the British Columbia Centre for Excellence 
(BC-CfE) between 2008 and 2011. Baseline population characteristics and treat-
ment efficacy were modified to reflect the observational cohort in the model, and 
mean changes in CD4+ cell-count and incidence rates of AIDS-related events were 
simulated in ARAMIS-DTG. The impact of relevant ARAMIS parameters on these 
outcomes, such as mortality or virological suppression, was assessed in sensitivity 
analyses. Results: In the base case analysis, the average CD4+ cell-count over five 
years increased from 295 to 682 cells/µL in ARAMIS-DTG and from 303 to 532 cells/
µL in the BC-CfE cohort, reflecting a potential overestimation of adherence in the 
clinical trial setting. However, despite a higher CD4+ cell-count, the incidence of 
AIDS-related events was also higher in ARAMIS: 3.81 vs. 2.84 per 100,000 person-
years, suggesting the higher incidence of AIDS-related events in ARAMIS-DTG was 
mostly attributable to the pre-2005 rates used to inform the model. Sensitivity analy-
ses produced similar results without adjusting ARAMIS-DTG to the BC-CfE cohort 
characteristics. cOnclusiOns: Although results highlight the need for calibrating 
economic models and accounting for factors such as adherence to achieve better 
alignment with real life data, in the particular case of ARAMIS-DTG the differences 
between simulated and observed outcomes did not significantly affect its overall 
cost-effectiveness outcomes.
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Objectives: Our objective was to evaluate the cost-effectiveness of currently 
recommended pharmacotherapies [response-guided triple therapies with 
pegylated-interferon plus ribavarin (PR) plus boceprevir (BOC) or telaprevir (TVR) or 
simeprevir (SIM) or sofosbuvir (SOF)] for the treatment of newly diagnosed patients 
with genotype 1 chronic hepatitis C virus (HCV) infection, from payer’s perspec-
tive. MethOds: A Markov cohort model was developed to simulate the disease 
progression of treatment naïve HCV patients initiating therapy. The model included 
the following outcomes: sustained virologic response (SVR) i.e. absence of detect-
able RNA of virus in blood serum at 12/24 weeks after ending treatment, relapse 
